Novavax (NASDAQ:NVAX) shares climbed 12% premarket on Monday after the U.S. FDA lifted clinical hold on the investigational ...
With its significant cash infusions from offloading its COVID assets, Novavax had just over $1 billion as it exited Q3, 2024.
Novavax NVAX announced that it has started dosing participants in the phase III study evaluating its experimental COVID-19-influenza combination (CIC) and stand-alone influenza vaccine candidates.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback